Praluent for patients with hypercholesterolaemia and mixed dyslipidaemia, or poor responders to statins, recommended for approval
The European Medicines Agency ( EMA ) has recommended the granting of a marketing authorisation for Praluent ( Alirocumab ) to lower high levels of cholesterol in the blood of people who are unable to ...
read article